Finance

Lists
Outlook: 63.3% bullish·3.3% bearish
Go to analysis
INO:NASDAQ
Inovio Pharmaceuticals Inc
US$1.46
0.00%
(0.00) 1D
US$1.43
-2.32% (-0.034)
Pre-market
Closed: ኖቬም 12, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Mkt. cap
272.54 ሚ
Avg. vol.
19.26 ሚ
Volume
123.14 ሺ
52-wk high
US$2.72
52-wk low
US$0.56
EPS
-US$0.80
Beta
1.71
Shares outstanding
187.31 ሚ
No. of employees
112
Mkt. cap
272.54 ሚ
Avg. vol.
19.26 ሚ
Volume
123.14 ሺ
52-wk high
US$2.72
52-wk low
US$0.56
EPS
-US$0.80
Beta
1.71
Shares outstanding
187.31 ሚ
No. of employees
112
News stories
From web sources and news partners
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current US$1.46
US$8.00 (+447.95%)
Average
US$6.33 (+333.56%)
Lowest
US$5.00 (+242.47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$5.00
+242.5%
11/12/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
US$6.00
+311%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
US$8.00
+447.9%
11/06/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
US$13.00
+790.4%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
-
-
-
-
Cost of goods sold
13.33 ሚ
10.26 ሚ
14.07 ሚ
10.83 ሚ
Cost of revenue
13.33 ሚ
10.26 ሚ
14.07 ሚ
10.83 ሚ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.88 ሚ
7.22 ሚ
7.88 ሚ
7.80 ሚ
Operating expense
7.88 ሚ
7.22 ሚ
7.88 ሚ
7.80 ሚ
Total operating expenses
21.21 ሚ
17.48 ሚ
21.95 ሚ
18.62 ሚ
Operating income
-21.21 ሚ
-17.48 ሚ
-21.95 ሚ
-18.62 ሚ
Other non operating income
-24.27 ሚ
21.17 ሚ
4.14 ሚ
12.73 ሚ
EBT including unusual items
-45.50 ሚ
3.76 ሚ
-19.68 ሚ
-6.01 ሚ
EBT excluding unusual items
-45.52 ሚ
3.75 ሚ
-19.48 ሚ
-5.53 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45.50 ሚ
3.76 ሚ
-19.68 ሚ
-6.01 ሚ
Net profit margin
-
-
-
-
Earnings per share
-0.87
-0.28
-0.31
-0.24
Interest and investment income
552.11 ሺ
449.34 ሺ
439.59 ሺ
363.85 ሺ
Interest expense
-
-
-
-
Net interest expenses
552.11 ሺ
449.34 ሺ
439.59 ሺ
363.85 ሺ
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.86 ሚ
-17.14 ሚ
-21.63 ሚ
-18.30 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች